会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 24. 发明申请
    • RECOMBINANT SPECIFIC BINDING PROTEIN
    • 重组特异性结合蛋白
    • WO1994009131A1
    • 1994-04-28
    • PCT/GB1993002133
    • 1993-10-15
    • SCOTGEN LIMITEDHARRIS, William, JosephEMERY, Stephen, CharlesWINTER, Gregory, PaulCARR, Francis, JosephMCGREGOR, Duncan, Patrick
    • SCOTGEN LIMITED
    • C12N15/12
    • C07K16/468A61K38/00
    • A specific binding protein having first and second binding regions, e.g. antibody Fv fragments, which specifically recognise and bind to target entities, said binding regions being contained at least in part on respectively first and second polypeptide chains, said chains additionally incorporating respectively first and second associating domains, e.g. antibody VH and VL domains, which are capable of binding to each other, causing the first and second polypeptide chains to combine, thereby providing a single protein incorporating the binding specificities of said first and second binding regions. The first and second binding regions may recognise different target entities, giving a bispecific binding protein. Preferably the associating domains are derived from a human protein (i.e. one which has been exposed to the human immune system), so that the protein is less likely to provoke the human immune system when administered therapeutically. The binding protein is suitably produced by recombinant DNA expression.
    • 具有第一和第二结合区的特异性结合蛋白,例如 抗体Fv片段,其特异性识别并结合靶物质,所述结合区至少部分地分别包含第一和第二多肽链,所述链另外包含第一和第二缔合结构域,例如, 抗体VH和VL结构域,其能够彼此结合,导致第一和第二多肽链结合,从而提供掺入所述第一和第二结合区的结合特异性的单一蛋白质。 第一和第二结合区可以识别不同的靶实体,得到双特异性结合蛋白。 优选地,缔合结构域衍生自人蛋白质(即已经暴露于人类免疫系统的蛋白质),使得当治疗施用时蛋白质不太可能引起人免疫系统。 结合蛋白通过重组DNA表达适当地产生。
    • 26. 发明申请
    • ALTERED ANTIBODIES, PRODUCTS AND PROCESSES RELATING THERETO
    • 改变的抗体,产品和工艺与此有关
    • WO1993017105A1
    • 1993-09-02
    • PCT/GB1993000363
    • 1993-02-19
    • SCOTGEN LIMITEDWINTER, Gregory, PaulCARR, Francis, JosephHARRIS, William, Joseph
    • SCOTGEN LIMITED
    • C12N15/13
    • C07K16/1027A61K38/00C07K16/465C07K2317/24
    • The present invention relates to altered antibodies which are substantially immuno silent by virtue of their containing selected germ-line amino acid residues which replace one or more corresponding somatically mutated residues in a native antibody. In a process for making a gene for use in preparing such an antibody, one or more somatically mutated amino acid residues in a native antibody are identified as suitable candidate(s) for alteration. A nucleotide coding sequence is made which codes for selected germ-line amino acid residues to replace the one or more somatically mutated amino acid residues. The altered antibody can have variable (V) regions which comprise complementarity determining regions (CDRs) which provide the antibody with capacity to bind a specific antigen; and a selected and predominantly germ-line framework. In processes for making a gene for use in the preparation of such an antibody, there are the steps of (i) obtaining CDR encoding nucleotide sequences which encode CDRs with specificity for the specific antigen and (ii) combining these CDR encoding nucleotide sequences with framework encoding nucleotide sequences which encode the selected germ-line framework.
    • 本发明涉及通过其含有选择的天然抗体中一个或多个相应的体细胞突变残基的选择的种系氨基酸残基基本上免疫沉默的抗体。 在制备用于制备这种抗体的基因的方法中,天然抗体中的一个或多个体细胞突变的氨基酸残基被鉴定为用于改变的合适的候选物。 编码编码选择的种系氨基酸残基以代替一个或多个体细胞突变的氨基酸残基的核苷酸编码序列。 改变的抗体可以具有可变(V)区,其包含提供抗体结合特异性抗原的能力的互补决定区(CDR); 和所选择的并且主要种系框架。 在制备用于制备这种抗体的基因的方法中,存在以下步骤:(i)获得CDR编码核苷酸序列,其编码对特异性抗原具有特异性的CDR,以及(ii)将这些CDR编码核苷酸序列与框架 编码所选择的种系框架编码核苷酸序列。